◀ Back to PCNA

CCL2 — PCNA

Protein-Protein interactions - manually collected from original source literature:

Studies that report less than 10 interactions are marked with *

• IRef Biogrid Interaction: PCNA — CCL2 (physical association, affinity chromatography technology) Bronze-da-Rocha et al., International journal of biological sciences 2011*

Text-mined interactions from Literome

Selzman et al., Am J Physiol Heart Circ Physiol 2002 : Immunohistochemistry and Western blot analysis revealed that MCP-1 increased both proliferating nuclear cell antigen and cyclin A expression
Abraham et al., J Cell Biochem 2003 : Major findings were upregulation of several genes associated with cell cycle progression, including cyclin E and D ; downregulation of cyclin dependent kinase inhibitors p21 and p27, cyclin dependent kinases 2, 5, and 6, and monocyte chemoattractant protein-1 ; and upregulation of growth factors, including vascular endothelial growth factor ( VEGF ) and vascular endothelial growth factor receptor I ( VEGFRI ), endothelial growth factor (EGF) and hepatic derived growth factor (HDGF)
Li et al., Fertil Steril 2012 (Endometriosis) : The CCL2 can increase the expression of proliferating cell nuclear antigen , survivin, and matrix metalloproteinase 2, and decrease the expression of tissue inhibitor of metalloproteinase 1 and 2, and promote the viability, proliferation and invasiveness of ESCs by activating Akt and MAPK/Erk1/2 signal pathway, but not p38 and JNK signal pathway